Carbidopa Hydrate

Research use only, not for human use.

An inhibitor of DOPA decarboxylase, preventing conversion of levodopa to dopamine.

An inhibitor of DOPA decarboxylase, preventing conversion of levodopa to dopamine. It is used in parkinson disease to reduce peripheral adverse effects of levodopa. It has no antiparkinson actions by itself.

Carbidopa ((S)-(-)-Carbidopa) monohydrate exhibits activities similar to that described for other AhR ligands in BχPC3 and Capan-2 cells, namely the induction of CYP1A1 and CYP1A2, which are inhibited by AhR antagonists such as CH223191.Carbidopa, a aromatic-L-amino acid decarboxylase inhibitor, is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Carbidopa is lethal (IC50=29 μM).

Carbidopa monohydrate also induces nuclear uptake of the AhR, and in vivo studies show that carbidopa at a dose of 1 mg/mouse significantly inhibits tumor growth in athymic nude mice bearing BχPC3 cells as xenografts.

——

Metabolic Enzyme/Protease

Decarboxylase

aromatic-L-amino-acid decarboxylase

——

——

38821-49-7

244.24

C10H16N2O5

>98% (HPLC)

DMSO: 10 mM

C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN.O

——

(-20℃)

With Ice Pack

≥ 2 years